S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(-0.03%) $0.926
USD/NOK
(-0.09%) $10.83
USD/GBP
(-0.14%) $0.791
USD/RUB
(-0.24%) $92.35

Realtime updates for 3SBio Inc [1530.HK]

Exchange: HKSE Sector: Biotechnology Industry: Biotechnology
Last Updated28 Mar 2024 @ 04:08

4.18% HKD 5.98

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 04:08):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...

Stats
Today's Volume 15.87M
Average Volume 16.86M
Market Cap 14.34B
EPS HKD0 ( 2024-03-20 )
Last Dividend HKD0.100 ( 2023-06-27 )
Next Dividend HKD0 ( N/A )
P/E 8.93
ATR14 HKD0.00800 (0.13%)

Volume Correlation

Long: 0.21 (neutral)
Short: -0.44 (neutral)
Signal:(33.235) Neutral

3SBio Inc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

3SBio Inc Correlation - Currency/Commodity

The country flag -0.09
( neutral )
The country flag -0.22
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.52
( weak negative )

3SBio Inc Financials

Annual 2022
Revenue: HKD6.86B
Gross Profit: HKD5.67B (82.69 %)
EPS: HKD0.780
Q2 2023
Revenue: HKD1.89B
Gross Profit: HKD1.60B (84.61 %)
EPS: HKD0.200
Q1 2023
Revenue: HKD1.89B
Gross Profit: HKD1.60B (84.61 %)
EPS: HKD0.200
Q4 2022
Revenue: HKD1.88B
Gross Profit: HKD1.55B (82.45 %)
EPS: HKD0.190

Financial Reports:

No articles found.

3SBio Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0.100
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

3SBio Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.93 - Stable (18.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend HKD0.0685 2018-06-29
Last Dividend HKD0.100 2023-06-27
Next Dividend HKD0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 3 --
Total Paid Out HKD0.369 --
Avg. Dividend % Per Year 0.00% --
Score 2.8 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 5.93
Div. Directional Score 8.57 --
Next Divdend (Est)
(2026-02-03)
HKD0 Estimate 2.75 %
Dividend Stability
0.22 Very Poor
Dividend Score
2.80
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
9919.HK Ex Dividend Knight 2023-08-24 Semi-Annually 0 0.00%
2182.HK Ex Dividend Knight 2023-06-12 Annually 0 0.00%
1199.HK Ex Dividend Junior 2023-09-11 Semi-Annually 0 0.00%
0285.HK Ex Dividend Junior 2023-06-13 Annually 0 0.00%
3888.HK Ex Dividend Knight 2023-06-02 Annually 0 0.00%
1772.HK Ex Dividend Knight 2023-07-03 Annually 0 0.00%
0817.HK Ex Dividend Junior 2023-09-18 Semi-Annually 0 0.00%
2342.HK Ex Dividend Knight 2023-09-07 Annually 0 0.00%
1336.HK Ex Dividend Knight 2023-07-06 Annually 0 0.00%
0392.HK Ex Dividend Junior 2023-09-22 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2571.5004.867.29[0 - 0.5]
returnOnAssetsTTM0.08381.2007.218.65[0 - 0.3]
returnOnEquityTTM0.1471.5009.4810.00[0.1 - 1]
payoutRatioTTM0.215-1.0007.85-7.85[0 - 1]
currentRatioTTM2.880.8000.6010.481[1 - 3]
quickRatioTTM2.250.8001.4691.175[0.8 - 2.5]
cashRatioTTM0.5821.5007.8810.00[0.2 - 2]
debtRatioTTM0.215-1.5006.42-9.64[0 - 0.6]
interestCoverageTTM13.371.0006.166.16[3 - 30]
operatingCashFlowPerShareTTM0.9152.009.6910.00[0 - 30]
freeCashFlowPerShareTTM0.5302.009.7410.00[0 - 20]
debtEquityRatioTTM0.368-1.5008.53-10.00[0 - 2.5]
grossProfitMarginTTM0.8351.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM0.3101.0005.805.80[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4611.0008.558.55[0.2 - 2]
assetTurnoverTTM0.3260.800-1.160-0.928[0.5 - 2]
Total Score11.22

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM7.011.0009.390[1 - 100]
returnOnEquityTTM0.1472.509.6710.00[0.1 - 1.5]
freeCashFlowPerShareTTM0.5302.009.8210.00[0 - 30]
dividendYielPercentageTTM1.8411.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM0.9152.009.6910.00[0 - 30]
payoutRatioTTM0.2151.5007.85-7.85[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3031.0004.910[0.1 - 0.5]
Total Score5.93

3SBio Inc

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators